JP2014503574A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503574A5
JP2014503574A5 JP2013550886A JP2013550886A JP2014503574A5 JP 2014503574 A5 JP2014503574 A5 JP 2014503574A5 JP 2013550886 A JP2013550886 A JP 2013550886A JP 2013550886 A JP2013550886 A JP 2013550886A JP 2014503574 A5 JP2014503574 A5 JP 2014503574A5
Authority
JP
Japan
Prior art keywords
compound
group
formula
optionally substituted
nitrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013550886A
Other languages
English (en)
Japanese (ja)
Other versions
JP5931926B2 (ja
JP2014503574A (ja
Filing date
Publication date
Priority claimed from FR1150651A external-priority patent/FR2970967B1/fr
Application filed filed Critical
Publication of JP2014503574A publication Critical patent/JP2014503574A/ja
Publication of JP2014503574A5 publication Critical patent/JP2014503574A5/ja
Application granted granted Critical
Publication of JP5931926B2 publication Critical patent/JP5931926B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013550886A 2011-01-27 2012-01-27 医薬としてのアザインダゾールまたはジアザインダゾール型の誘導体 Active JP5931926B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1150651 2011-01-27
FR1150651A FR2970967B1 (fr) 2011-01-27 2011-01-27 Derives de type azaindazole ou diazaindazole comme medicament
PCT/EP2012/051283 WO2012101239A1 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament

Publications (3)

Publication Number Publication Date
JP2014503574A JP2014503574A (ja) 2014-02-13
JP2014503574A5 true JP2014503574A5 (enExample) 2015-02-26
JP5931926B2 JP5931926B2 (ja) 2016-06-08

Family

ID=44318089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013550886A Active JP5931926B2 (ja) 2011-01-27 2012-01-27 医薬としてのアザインダゾールまたはジアザインダゾール型の誘導体

Country Status (30)

Country Link
US (2) US20130172360A1 (enExample)
EP (1) EP2668184B1 (enExample)
JP (1) JP5931926B2 (enExample)
KR (2) KR101923751B1 (enExample)
CN (1) CN103339129B (enExample)
AR (1) AR084935A1 (enExample)
AU (1) AU2012210467B2 (enExample)
BR (1) BR112013018852B1 (enExample)
CA (1) CA2823824C (enExample)
CY (1) CY1120088T1 (enExample)
DK (1) DK2668184T3 (enExample)
ES (1) ES2661695T3 (enExample)
FR (1) FR2970967B1 (enExample)
HR (1) HRP20180524T1 (enExample)
HU (1) HUE037153T2 (enExample)
IL (2) IL227496B (enExample)
LT (1) LT2668184T (enExample)
MA (1) MA34903B1 (enExample)
MX (1) MX356411B (enExample)
MY (1) MY180666A (enExample)
PL (1) PL2668184T3 (enExample)
PT (1) PT2668184T (enExample)
RS (1) RS57101B1 (enExample)
RU (1) RU2600976C2 (enExample)
SI (1) SI2668184T1 (enExample)
TN (1) TN2013000293A1 (enExample)
TR (1) TR201802944T4 (enExample)
TW (1) TWI546303B (enExample)
UA (1) UA109698C2 (enExample)
WO (1) WO2012101239A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
AU2013222345B2 (en) 2012-02-22 2017-09-07 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as TNAP inhibitors
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
EP2689779A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10211205B2 (en) * 2016-04-27 2019-02-19 International Business Machines Corporation Field effect transistor structure for reducing contact resistance
CN108570052A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CA3098988A1 (en) 2018-05-02 2019-11-07 Jw Pharmaceutical Corporation Heterocycle derivative
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GB2606804B (en) 2019-07-17 2023-12-27 2692372 Ontario Inc Benzenesulfonamide derivatives and uses thereof
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
PY2089151A (es) * 2019-12-31 2022-05-11 Ifm Due Inc Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN115916771B (zh) * 2020-04-02 2025-04-01 浙江华海药业股份有限公司 多靶点的抗肿瘤化合物及其制备方法和应用
US20240018153A1 (en) 2020-11-20 2024-01-18 2692372 Ontario, Inc. Benzenesulfonamide derivatives and uses thereof
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9808281A (pt) * 1997-03-19 2000-05-16 Basf Ag Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
YU93902A (sh) 2000-06-22 2005-11-28 Pfizer Products Inc. Postupak za pripremanje pirazolopirimidinona
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
EP1919913A2 (en) * 2005-08-25 2008-05-14 F.Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
WO2008010964A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
WO2008074749A1 (en) 2006-12-20 2008-06-26 Nerviano Medical Sciences S.R.L. Indazole derivatives as kinase inhibitors for the treatment of cancer
EA018503B1 (ru) 2007-07-20 2013-08-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные как ингибиторы киназы
WO2010069966A1 (en) 2008-12-18 2010-06-24 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament

Similar Documents

Publication Publication Date Title
JP2019524883A5 (enExample)
JP2014510774A5 (enExample)
JP2015522650A5 (enExample)
CN109715626A (zh) 作为fgfr抑制剂的杂环化合物
JP2016516043A5 (enExample)
JP2011509309A5 (enExample)
JP2017509586A5 (enExample)
JP2019522055A5 (enExample)
JP2017528467A5 (enExample)
JP2017511360A5 (enExample)
JP2010540508A5 (enExample)
JP2008510770A5 (enExample)
JP2011529054A5 (enExample)
JP2018529690A5 (enExample)
JP2016513696A5 (enExample)
JP2017528498A5 (enExample)
JP2011523412A5 (enExample)
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
JP2011509302A5 (enExample)
JP2014532716A5 (enExample)
JP2013542267A5 (enExample)
JP2023552610A5 (enExample)
JP2017506666A5 (enExample)
JP2019535723A5 (enExample)
JP2009539943A5 (enExample)